✦ LIBER ✦

High-dose epirubicin prolongs survival for women with poor prognosis node-positive breast cancer

✍ Scribed by Raimund Jakesz

Book ID: 114483779
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 146 KB
Volume: 2
Category: Article
ISSN: 1363-4054
DOI: 10.1054/ebon.2001.0122

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-dense treatment prolongs disease-fr

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer

✍ Chau Dang; Andrew D Seidman 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Severe adverse reaction to high dose epi

Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer

✍ TURTLE, C. J. ;KEEFE, D. M. K. ;BELL, D. ;WHEELER, H. ;MA, D. D. F. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB

High Ep-CAM Expression is Associated wit

High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer

✍ Gilbert Spizzo; Guenther Gastl; Peter Obrist; Philip Went; Stephan Dirnhofer; Su 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 327 KB

High-dose mitoxantrone adjuvant chemothe

High-dose mitoxantrone adjuvant chemotherapy does not prolong survival for women with breast cancer and ten or more involved axillary nodes

✍ Gabriel N Hortobagyi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 225 KB

High CCND1 amplification identifies a gr

High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer

✍ Pankaj G. Roy; Norman Pratt; Colin A. Purdie; Lee Baker; Alison Ashfield; Phil Q 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 265 KB

## Abstract __CCND1__ encodes for the cyclin D1 protein involved in G1/S cell cycle transition. In breast cancer the mechanism of __CCND1__ amplification, relationship between cyclin D1 protein expression and the key clinical markers estrogen receptor (ER) and HER2 requires elucidation. Tissue micr

Adding medroxyprogesterone to adjuvant c

Adding medroxyprogesterone to adjuvant chemotherapy prolongs survival for women over 60 with node-positive breast cancer but is detrimental for those under 40

✍ Naira Chobanyan 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 120 KB